{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:25:59Z","timestamp":1792783559421,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Tel Aviv University","id":[{"id":"https:\/\/ror.org\/04mhzgx49","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hormones"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s42000-026-00759-2","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T19:24:12Z","timestamp":1773948252000},"page":"365-375","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["RET Lys666Asn has a low rate of MEN2-related tumors but may be associated with pheochromocytoma"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8137-667X","authenticated-orcid":false,"given":"Reut","family":"Halperin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naama","family":"Peshes-Yaloz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Tirosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orit","family":"Twito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,19]]},"reference":[{"key":"759_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-024-02366-7","author":"F Cetani","year":"2024","unstructured":"Cetani F, Dinoi E, Pierotti L, Pardi E (2024) Familial states of primary hyperparathyroidism: an update. J Endocrinol Invest. https:\/\/doi.org\/10.1007\/s40618-024-02366-7","journal-title":"J Endocrinol Invest"},{"issue":"6","key":"759_CR2","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1089\/thy.2014.0335","volume":"25","author":"SAJ Wells","year":"2015","unstructured":"Wells SAJ, Asa SL, Dralle H et al (2015) Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 25(6):567\u2013610. https:\/\/doi.org\/10.1089\/thy.2014.0335","journal-title":"Thyroid"},{"key":"759_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.932353","volume":"12","author":"AT Regua","year":"2022","unstructured":"Regua AT, Najjar M, Lo H-W (2022) RET signaling pathway and RET inhibitors in human cancer. Front Oncol 12:932353. https:\/\/doi.org\/10.3389\/fonc.2022.932353","journal-title":"Front Oncol"},{"key":"759_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16030494","author":"T Binter","year":"2024","unstructured":"Binter T, Baumgartner-Parzer S, Schernthaner-Reiter MH et al (2024) Does genotype-specific phenotype in patients with multiple endocrine neoplasia type 2 occur as current guidelines predict? Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers16030494","journal-title":"Cancers (Basel)"},{"key":"759_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/CCO.0000000000001009","volume":"36","author":"A Machens","year":"2024","unstructured":"Machens A, Dralle H (2024) Multiple endocrine neoplasia type 2: towards a risk-based approach integrating molecular and biomarker results. Curr Opin Oncol 36:1\u201312. https:\/\/doi.org\/10.1097\/CCO.0000000000001009","journal-title":"Curr Opin Oncol"},{"key":"759_CR6","unstructured":"Minns R, Koch C (2024) Multiple endocrine neoplasia type 2. Clinical Overview. In: ClinicalKey,Elsevier. https:\/\/www.clinicalkey.com\/#!\/content\/clinical_overview\/67-s2.0-MC025"},{"key":"759_CR7","doi-asserted-by":"publisher","first-page":"e734","DOI":"10.1210\/clinem\/dgad156","volume":"108","author":"A Machens","year":"2023","unstructured":"Machens A, Lorenz K, Brandenburg T et al (2023) The changing face of multiple endocrine neoplasia 2A: from symptom-based to preventative medicine. J Clin Endocrinol Metab 108:e734\u2013e742. https:\/\/doi.org\/10.1210\/clinem\/dgad156","journal-title":"J Clin Endocrinol Metab"},{"key":"759_CR8","doi-asserted-by":"publisher","first-page":"4264","DOI":"10.1210\/jc.2019-00516","volume":"104","author":"F Raue","year":"2019","unstructured":"Raue F, Bruckner T, Frank-Raue K (2019) Long-term outcomes and aggressiveness of hereditary medullary thyroid carcinoma: 40 years of experience at one center. J Clin Endocrinol Metab 104:4264\u20134272. https:\/\/doi.org\/10.1210\/jc.2019-00516","journal-title":"J Clin Endocrinol Metab"},{"key":"759_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13215554","author":"A Prete","year":"2021","unstructured":"Prete A, Matrone A, Gambale C et al (2021) Active surveillance in RET gene carriers belonging to families with multiple endocrine neoplasia. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers13215554","journal-title":"Cancers (Basel)"},{"key":"759_CR10","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1530\/EJE-09-0929","volume":"162","author":"M Muzza","year":"2010","unstructured":"Muzza M, Cordella D, Bombled J et al (2010) Four novel RET germline variants in exons 8 and 11 display an oncogenic potential in vitro. Eur J Endocrinol 162:771\u2013777. https:\/\/doi.org\/10.1530\/EJE-09-0929","journal-title":"Eur J Endocrinol"},{"key":"759_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/life13061332","author":"V Neocleous","year":"2023","unstructured":"Neocleous V, Fanis P, Frangos S et al (2023) RET proto-oncogene variants in patients with medullary thyroid carcinoma from the Mediterranean Basin: a brief report. Life. https:\/\/doi.org\/10.3390\/life13061332","journal-title":"Life"},{"key":"759_CR12","doi-asserted-by":"publisher","first-page":"1268193","DOI":"10.3389\/fendo.2023.1268193","volume":"14","author":"RC Rosenblum","year":"2023","unstructured":"Rosenblum RC, Hirsch D, Grozinsky-Glasberg S et al (2023) Clinical characteristics of a large familial cohort with medullary thyroid cancer and germline Cys618Arg RET mutation in an Israeli multicenter study. Front Endocrinol (Lausanne) 14:1268193. https:\/\/doi.org\/10.3389\/fendo.2023.1268193","journal-title":"Front Endocrinol (Lausanne)"},{"key":"759_CR13","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1089\/thy.2016.0374","volume":"26","author":"JY Xu","year":"2016","unstructured":"Xu JY, Grubbs EG, Waguespack SG et al (2016) Medullary thyroid carcinoma associated with germline RET(K666N) mutation. Thyroid 26:1744\u20131751. https:\/\/doi.org\/10.1089\/thy.2016.0374","journal-title":"Thyroid"},{"key":"759_CR14","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1507\/endocrj.ej14-0334","volume":"61","author":"M Yamazaki","year":"2014","unstructured":"Yamazaki M, Hanamura T, Ito K et al (2014) A newly identified missense mutation in RET codon 666 is associated with the development of medullary thyroid carcinoma. Endocr J 61:1141\u20131144. https:\/\/doi.org\/10.1507\/endocrj.ej14-0334","journal-title":"Endocr J"},{"key":"759_CR15","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1089\/thy.2016.0399","volume":"27","author":"M Lebeault","year":"2017","unstructured":"Lebeault M, Pinson S, Guillaud-Bataille M et al (2017) Nationwide French study of RET variants detected from 2003 to 2013 suggests a possible influence of polymorphisms as modifiers. Thyroid 27:1511\u20131522. https:\/\/doi.org\/10.1089\/thy.2016.0399","journal-title":"Thyroid"},{"key":"759_CR16","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1210\/jc.2017-02402","volume":"103","author":"T Jaber","year":"2018","unstructured":"Jaber T, Hyde SM, Cote GJ et al (2018) A homozygous RET K666N genotype with an MEN2A phenotype. J Clin Endocrinol Metab 103:1269\u20131272. https:\/\/doi.org\/10.1210\/jc.2017-02402","journal-title":"J Clin Endocrinol Metab"},{"key":"759_CR17","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1530\/ERC-10-0306","volume":"18","author":"MG Borrello","year":"2011","unstructured":"Borrello MG, Aiello A, Peissel B et al (2011) Functional characterization of the MTC-associated germline RET-K666E mutation: evidence of oncogenic potential enhanced by the G691S polymorphism. Endocr Relat Cancer 18:519\u2013527. https:\/\/doi.org\/10.1530\/ERC-10-0306","journal-title":"Endocr Relat Cancer"},{"key":"759_CR18","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/S1525-1578(10)60556-9","volume":"7","author":"SA Ahmed","year":"2005","unstructured":"Ahmed SA, Snow-Bailey K, Highsmith WE et al (2005) Nine novel germline gene variants in the RET proto-oncogene identified in twelve unrelated cases. J Mol Diagn 7:283\u2013288. https:\/\/doi.org\/10.1016\/S1525-1578(10)60556-9","journal-title":"J Mol Diagn"},{"key":"759_CR19","doi-asserted-by":"publisher","unstructured":"La Greca A, Dawes D, Albuja-Cruz M, et al (2024) MEN2 phenotype in a family with germline heterozygous rare RET K666N variant. Endocrinol Diabetes Metab Case Rep 2024:. https:\/\/doi.org\/10.1530\/EDM-24-0009","DOI":"10.1530\/EDM-24-0009"},{"key":"759_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1007352","volume":"14","author":"L Yehia","year":"2018","unstructured":"Yehia L, Ni Y, Sesock K et al (2018) Unexpected cancer-predisposition gene variants in Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome patients without underlying germline PTEN mutations. PLoS Genet 14:e1007352. https:\/\/doi.org\/10.1371\/journal.pgen.1007352","journal-title":"PLoS Genet"},{"key":"759_CR21","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1136\/jmedgenet-2015-103218","volume":"52","author":"M Curr\u00e1s-Freixes","year":"2015","unstructured":"Curr\u00e1s-Freixes M, Inglada-P\u00e9rez L, Mancikova V et al (2015) Recommendations for somatic and germline genetic testing of single pheochromocytoma and paraganglioma based on findings from a series of 329 patients. J Med Genet 52:647\u2013656. https:\/\/doi.org\/10.1136\/jmedgenet-2015-103218","journal-title":"J Med Genet"},{"key":"759_CR22","unstructured":"Clinvar No Title. National Center for Biotechnology Information ClinVar; [VCV00002493250], https:\/\/www.ncbi.nlm.nih.gov\/clinvar\/variation\/VCV00002493250 (accessed Aug 13, 2024)"},{"key":"759_CR23","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1093\/ejendo\/lvad126","volume":"189","author":"A Vuylsteke","year":"2023","unstructured":"Vuylsteke A, Hannes L, Brems H et al (2023) Germline founder variant c.1998delinsTTCT in the RET oncogene: a cohort study in 15 Belgian families. Eur J Endocrinol 189:402\u2013408. https:\/\/doi.org\/10.1093\/ejendo\/lvad126","journal-title":"Eur J Endocrinol"},{"key":"759_CR24","doi-asserted-by":"publisher","first-page":"R15","DOI":"10.1530\/EJE-21-0753","volume":"186","author":"RMB Maciel","year":"2021","unstructured":"Maciel RMB, Maia AL (2021) Global endocrinology: geographical variation in the profile of RET variants in patients with medullary thyroid cancer: a comprehensive review. Eur J Endocrinol 186:R15\u2013R30. https:\/\/doi.org\/10.1530\/EJE-21-0753","journal-title":"Eur J Endocrinol"},{"key":"759_CR25","doi-asserted-by":"publisher","first-page":"21332","DOI":"10.18632\/oncotarget.7237","volume":"7","author":"N Wang","year":"2016","unstructured":"Wang N, Kjellin H, Sofiadis A et al (2016) Genetic and epigenetic background and protein expression profiles in relation to telomerase activation in medullary thyroid carcinoma. Oncotarget 7:21332\u201321346. https:\/\/doi.org\/10.18632\/oncotarget.7237","journal-title":"Oncotarget"},{"key":"759_CR26","doi-asserted-by":"publisher","first-page":"4275","DOI":"10.1210\/jc.2017-02529","volume":"103","author":"C Loveday","year":"2018","unstructured":"Loveday C, Josephs K, Chubb D et al (2018) P.Val804Met, the most frequent pathogenic mutation in RET, confers a very low lifetime risk of medullary thyroid cancer. J Clin Endocrinol Metab 103:4275\u20134282. https:\/\/doi.org\/10.1210\/jc.2017-02529","journal-title":"J Clin Endocrinol Metab"},{"key":"759_CR27","doi-asserted-by":"publisher","DOI":"10.1055\/s-2000-11001","volume":"108","author":"CA Koch","year":"2000","unstructured":"Koch CA, Huang SC, Vortmeyer AO et al (2000) A patient with MEN 2 and multiple mutations of RET in the germline. Exp Clin Endocrinol Diabetes 108:493","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"759_CR28","first-page":"6223","volume":"60","author":"SC Huang","year":"2000","unstructured":"Huang SC, Koch CA, Vortmeyer AO et al (2000) Duplication of the mutant RET allele in trisomy 10 or loss of the wild-type allele in multiple endocrine neoplasia type 2-associated pheochromocytomas. Cancer Res 60:6223\u20136226","journal-title":"Cancer Res"},{"key":"759_CR29","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s10689-004-7022-3","volume":"4","author":"CA Koch","year":"2005","unstructured":"Koch CA (2005) Molecular pathogenesis of MEN2-associated tumors. Fam Cancer 4:3\u20137. https:\/\/doi.org\/10.1007\/s10689-004-7022-3","journal-title":"Fam Cancer"},{"key":"759_CR30","doi-asserted-by":"publisher","first-page":"7809","DOI":"10.1038\/sj.onc.1204991","volume":"20","author":"CA Koch","year":"2001","unstructured":"Koch CA, Huang SC, Moley JF et al (2001) Allelic imbalance of the mutant and wild-type RET allele in MEN 2A-associated medullary thyroid carcinoma. Oncogene 20:7809\u20137811. https:\/\/doi.org\/10.1038\/sj.onc.1204991","journal-title":"Oncogene"},{"key":"759_CR31","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1210\/jc.2002-021254","volume":"88","author":"SC Huang","year":"2003","unstructured":"Huang SC, Torres-Cruz J, Pack SD et al (2003) Amplification and overexpression of mutant RET in multiple endocrine neoplasia type 2-associated medullary thyroid carcinoma. J Clin Endocrinol Metab 88:459\u2013463. https:\/\/doi.org\/10.1210\/jc.2002-021254","journal-title":"J Clin Endocrinol Metab"},{"key":"759_CR32","doi-asserted-by":"publisher","first-page":"L15","DOI":"10.1530\/ERC-21-0226","volume":"28","author":"A Mandl","year":"2021","unstructured":"Mandl A, Welch JM, Kapoor G et al (2021) Two distinct classes of thymic tumors in patients with MEN1 show LOH at the MEN1 locus. Endocr Relat Cancer 28:L15\u2013L19","journal-title":"Endocr Relat Cancer"},{"key":"759_CR33","doi-asserted-by":"publisher","first-page":"13163","DOI":"10.1111\/jcmm.15922","volume":"24","author":"Z Yang","year":"2020","unstructured":"Yang Z, Qi X, Gross N et al (2020) The synergy of germline C634Y and V292M RET mutations in a northern Chinese family with multiple endocrine neoplasia type 2A. J Cell Mol Med 24:13163\u201313170. https:\/\/doi.org\/10.1111\/jcmm.15922","journal-title":"J Cell Mol Med"},{"key":"759_CR34","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.4158\/ep15838.or","volume":"21","author":"A Verrienti","year":"2015","unstructured":"Verrienti A, Carbone A, Bellitti P et al (2015) A novel double mutation val648ile and val804leu of ret proto-oncogene in multiple endocrine neoplasia type 2. Endocr Pract 21:1248\u20131254. https:\/\/doi.org\/10.4158\/ep15838.or","journal-title":"Endocr Pract"}],"container-title":["Hormones"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s42000-026-00759-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s42000-026-00759-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s42000-026-00759-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T13:31:43Z","timestamp":1789565503000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s42000-026-00759-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,19]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["759"],"URL":"https:\/\/doi.org\/10.1007\/s42000-026-00759-2","relation":{},"ISSN":["1109-3099","2520-8721"],"issn-type":[{"value":"1109-3099","type":"print"},{"value":"2520-8721","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,19]]},"assertion":[{"value":"19 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Sheba Medical Center and Wolfson Medical Center.\u00a0Ethical approval numbers SMC-18\u20135674 & WMC-0143\u201321.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"RH, NPY, AT, and OT declare they have nothing to disclose.","order":3,"name":"Ethics","label":"Disclosure","group":{"name":"EthicsHeading","label":"Declarations"}}]}}